DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Information source: Innovative Medical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma

Intervention: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Innovative Medical

Official(s) and/or principal investigator(s):
Robert Noecker, MD, Principal Investigator, Affiliation: UPMC Eye Center

Summary

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

Clinical Details

Official title: Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female > 18 years of age

- Diagnosis of open-angle glaucoma or ocular hypertension

- IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation

- Presently on latanoprost monotherapy for at least 6 weeks

- Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

- · Known contraindication or allergy to brimonidine or any of its components

- Subjects must be naive to brimonidine 0. 2% or brimonidine Purite 0. 15% and

dorzolamide 2%

- Uncontrolled systemic disease

- Active ocular disease other than glaucoma or ocular hypertension (e. g. uveitis,

ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.

- Required use of ocular medications other than the study medications during the

study (intermittent use of artificial tear product is allowed).

- Corneal abnormalities

- History of intraocular surgery within the last 3 months

- Female patients of childbearing potential who are pregnant, lactating, planning

a pregnancy, or not using a reliable form of birth control

- Visual field loss, which in the opinion of the investigator, is functionally

significant, or evidence of progressive visual field loss within the last year.

Locations and Contacts

Dr. Noecker, Pittsburgh, Pennsylvania 15213, United States
Additional Information


Last updated: May 30, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017